Search

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Prioritizing mental health and well-being today and every day

Prioritizing Mental Health and Well-being Today and Everyday

Championing minds for generations both in and out of the workplace

Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

200 employees make a difference with record-breaking volunteer efforts

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

Boehringer Ingelheim launches vaccine to protect poultry from three diseases

What can the Patient do?

Embracing Differences: Our journey to diversity, equity, and inclusion

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

New Documentary Highlights Ranch’s Commitment to Cattle Health

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Expert insights: top online lung cancer questions answered

As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Boehringer Ingelheim Acquires AMAL Therapeutics

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Boehringer’s unique approach to innovation

Boehringer’s unique approach to driving patient-centric innovation

Corporate Compliance Program

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers